CA3067512A1 - Cannabidiolic acid esters compositions and uses thereof - Google Patents

Cannabidiolic acid esters compositions and uses thereof Download PDF

Info

Publication number
CA3067512A1
CA3067512A1 CA3067512A CA3067512A CA3067512A1 CA 3067512 A1 CA3067512 A1 CA 3067512A1 CA 3067512 A CA3067512 A CA 3067512A CA 3067512 A CA3067512 A CA 3067512A CA 3067512 A1 CA3067512 A1 CA 3067512A1
Authority
CA
Canada
Prior art keywords
branched
straight
compound according
disease
cbda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067512A
Other languages
English (en)
French (fr)
Inventor
Raphael Mechoulam
Linda Parker
Roger Pertwee
Aron WELLER
Joseph Tam
Christeen Haj
Reem Smoum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
University of Guelph
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Bar Ilan University filed Critical University of Guelph
Publication of CA3067512A1 publication Critical patent/CA3067512A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3067512A 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof Pending CA3067512A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3067512A1 true CA3067512A1 (en) 2018-12-27

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067512A Pending CA3067512A1 (en) 2017-06-20 2018-06-20 Cannabidiolic acid esters compositions and uses thereof

Country Status (12)

Country Link
US (1) US11440870B2 (https=)
EP (1) EP3509638B1 (https=)
JP (1) JP2020524679A (https=)
CN (2) CN121534035A (https=)
AU (1) AU2018287018B2 (https=)
BR (1) BR112019026916A2 (https=)
CA (1) CA3067512A1 (https=)
DK (1) DK3509638T3 (https=)
ES (1) ES2909350T3 (https=)
MX (1) MX389847B (https=)
PT (1) PT3509638T (https=)
WO (1) WO2018235079A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3509638B1 (en) 2017-06-20 2022-01-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020136648A1 (en) * 2018-12-25 2020-07-02 Epm Group Inc. Cannabidiolic acid esters for cosmetic or edible compositions
US12403114B2 (en) 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2021034403A1 (en) 2019-08-22 2021-02-25 Epm Group, Inc. Cannabinoid acid ester compositions and uses thereof
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
ATE277921T1 (de) 1998-05-04 2004-10-15 Univ Connecticut Selektiv auf den cb2-rezeptor wirkende cannabinoide
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
CA2623723A1 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
EP2842933B1 (de) * 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
US9701618B2 (en) * 2014-04-16 2017-07-11 Vivacell Biotechnology España S.L. Cannabidiol quinone derivatives
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
EP3509638B1 (en) 2017-06-20 2022-01-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
BR112019026916A2 (pt) 2020-06-30
JP2020524679A (ja) 2020-08-20
EP3509638A1 (en) 2019-07-17
AU2018287018A1 (en) 2020-01-30
AU2018287018B2 (en) 2022-04-28
WO2018235079A1 (en) 2018-12-27
ES2909350T3 (es) 2022-05-06
EP3509638B1 (en) 2022-01-12
PT3509638T (pt) 2022-03-02
DK3509638T3 (da) 2022-04-11
CN121534035A (zh) 2026-02-17
US20200115317A1 (en) 2020-04-16
MX2019015311A (es) 2022-02-02
CN111032088A (zh) 2020-04-17
MX389847B (es) 2025-03-20
US11440870B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
AU2018287018B2 (en) Cannabidiolic acid esters compositions and uses thereof
Pertwee et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats
EP2986289B1 (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
Jones et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
CN105517989B (zh) 大麻素类化合物的混合物及其制备和用途
ES2972711T3 (es) Tratamiento de enfermedades del CNS con estimuladores de la GCs
US20230218567A1 (en) Compound and method for treating diseases and disorders
CN102274227B (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
TW201805283A (zh) sGC刺激劑之固體形式
US8492431B2 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
MXPA06012564A (es) Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
CN101379063A (zh) 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
CN101016329A (zh) 以介芬胺为原料制备环杷明的方法
JP2024527932A (ja) カンナビノイドのホスフェートプロドラッグ
KR20120081120A (ko) 뉴로키닌 2 수용체 활성과 관련된 장애 또는 질환을 치료하기 위한 화합물
CN107446010A (zh) 一种红霉素衍生物及其制备方法和应用
CN102228696B (zh) 聚乙二醇-聚乙烯醇共聚物-美他沙酮前药及其合成方法
CN1318414C (zh) 含邻萘醌结构的化合物及其应用
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用
CN1690073A (zh) 甾体类衍生物
EP1940831A1 (en) Salicylate and gentisate salts of a piperazine compound
CN102408433B (zh) 含嘧啶的肟类化合物、其制备方法和用途
CN1736381B (zh) 吗啉甲基萘满酮用于制备平滑肌解痉剂的用途